F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
51 hedge funds and large institutions have $84.6M invested in F-star Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 3 reducing their positions, and 10 closing their positions.
833% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 3
60% more capital invested
Capital invested by funds: $52.9M → $84.6M (+$31.8M)
2% less funds holding
Funds holding: 52 → 51 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$8.53M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.14M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$3.01M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$2.37M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$2.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$745K |
| 2 |
Goldman Sachs
New York
|
-$276K |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$237K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$183K |
| 5 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$145K |
FSTX Hedge Fund Activity: Q3 2018 in Review
51 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q3 2018, worth a combined $84.6M — up 60% from $52.9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of FSTX and 9 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 28 added.
The largest buyer was Jennison Associates, opening a new position worth an estimated $8.53M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $745K sold.
- 51 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q3 2018, down from 52 in Q2 2018.
- Funds reported $84.6M of F-star Therapeutics, Inc. Common Stock stock for Q3 2018, up 60% quarter-over-quarter.
- 9 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q3 2018 and 10 closed out, a net change of -1 holder.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q3 2018 was Jennison Associates, an estimated $8.53M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q3 2018 was Alyeska Investment Group, an estimated $745K sold.
Based on aggregated 13F filings for Q3 2018.